MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This analysis reveals blast percentage and MECOM fusion partner alter overall survival in AML patients, suggesting treatment implications.

Patients with <20% blasts had a median overall survival of 17 months, while those with ≥20% blasts had a median of 9 months.
Multivariate analysis indicated that ≥20% blasts increased the risk of death by 90%, independent of treatment intensity or MECOM fusion partner.
Classic MECOM fusion partners appeared in 57% of patients, but variant partners were associated with improved outcomes for those with <20% blasts.
Intensive chemotherapy and low-intensity therapy showed similar complete remission rates, suggesting treatment options may vary for MECOM-r AML.

Jen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

This analysis reveals blast percentage and MECOM fusion partner alter overall survival in AML patients, suggesting treatment implications.

Patients with <20% blasts had a median overall survival of 17 months, while those with ≥20% blasts had a median of 9 months.
Multivariate analysis indicated that ≥20% blasts increased the risk of death by 90%, independent of treatment intensity or MECOM fusion partner.
Classic MECOM fusion partners appeared in 57% of patients, but variant partners were associated with improved outcomes for those with <20% blasts.
Intensive chemotherapy and low-intensity therapy showed similar complete remission rates, suggesting treatment options may vary for MECOM-r AML.

Jen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark